The effect of Simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle

American Journal of Cardiology

Volumn 77, Issue 10, 1996, Pages 851-854

  Laaksonen, Reijo ^a   Jokelainen, Kalle ^b   Laakso, Juha ^b   Sahi, Timo ^b   Härkönen, Matti ^b   Tikkanen, Matti Juhani ^b   Himberg, Jaakko Juhani ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ISOPRENOID; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; UBIQUINONE;

ADULT; ARTICLE; CELL RESPIRATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; HIGH ENERGY PHOSPHATE; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; MALE; MUSCLE BIOPSY; MUSCLE MITOCHONDRION; PRIORITY JOURNAL; RHABDOMYOLYSIS; SKELETAL MUSCLE;

ADENOSINE TRIPHOSPHATE; ADULT; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA; LOVASTATIN; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PHOSPHOCREATINE; SIMVASTATIN; UBIQUINONE;

EID: 0030012771     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)89180-1     Document Type: Article

References (25)

1. Feussner G. HMG CoA reductase Inhibitors. Curr Opin Lipidol 1994;5:59-68.
2. Grundy S. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319:24-33.
3. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430.
4. Lehninger AL. Principles of Biochemistry. 3rd ed. New York: Worth, 1982.
5. Grinlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, Greco AV, Littarru GP. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993;33:226-229.
6. Watts GF, Castelluccio C, Rice-Evans C, Taub NA, Baum H, Quinn PJ. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993;46:1055-1057.
7. Folkers K, Langsjoen P, Willis R, Richardson P, Xia L-J, Ye C-Q, Tamagava H. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990;87:8931-8934.
8. Willis R, Folkers K, Tucker J, Chun-Qu Y, Li-Jun X, Tamagava H. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci USA 1990;87:8928-8930.
9. Beyer RE, Nordenbrand K, Ernster L. The function of coenzyme Q in free radical production and as an antioxidant: a review. Chemica Scripta 1987;27:145-153.
10. Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg J-J. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in man. Clin Pharmacol Ther 1995;57:62-66.
11. Havel R, Eder H, Bragdon J. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34:1345-1353.
12. Näveri H, Rehunen S, Kuoppasalmi K, Tulikoura I, Härkönen M. Muscle metabolism during and after strenuous intermitted running. Scand J Clin Lab Invest 1978;38;329-336.
13. Lowry OH, Passonneau JV. A Flexible System of Enzymatic Analysis. New York: Academic Press, 1972.
14. Laaksonen R, Riihimäki A, Laitila M, Mårtensson K, Tikkanen MJ, Himberg J.-J. Serum and muscle tissue ubiquinone levels in healthy subjects. J Clin Lab Med 1995;25:517-21.
15. Jokelainen K, Salmela KS, Humaloja K, Roine R. Blood dolichol in lysosomal diseases. Biochem Cell Biol 1992;70:481-485.
16. De Leenheer AP, De Bevere V, De Ruyfer M, Claeys AE. Simultaneous determination of retinol and alpha-tocopherol in human serum by high-performance liquid chromatography. J Chromatogr 1979;162:408-413.
17. Nellis HJCF, De Leenheer AP. Isocratic nonaqueous reversed phase liquid chromatography of carotenoids. Anal Chem 1983;55:270-275.
18. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
19. Laaksonen R, Ojala J-P, Tikkanen MJ, Himberg J-J. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994;46:313-317.
20. Elmberger P, Engfeldt P, Dallner G. Presence of dolichol and its derivatives in human blood. J Lipid Res 1988;29:1651-1662.
21. Hoffman R, Brook G, Aviram M. Hypolipidemic drugs reduse lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis 1992;93:105-113.
22. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook JG. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism 1992;41:229-235.
23. Contermans J, Smit JW, Bär PR, Erkelens DW. A comparison of the effects of simvastatin and pravastatin monotherapy on muscle histology and permeability in hypercholesterolaemic patients. Br J Clin Pharmacol 1995;39:135-141.
24. Munro E, Patel M, Chan P, Betterridge L, Clunn G, Gallagher K, Huges A, Schachter M, Wolfe J, Sever P. Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest 1994;24:766-772.
25. Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB III, Ivanhoe R, Cedarholm JC, Stillabower ME, Tallay JD, DeMaio SJ, O'Neill WW, Frazier JE, Cohen-Bernstein CL, Robbins DC, Brown CL III, Alexander RW, and the lovastatin restenosis trial study group. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994;331:1331-1337.